Parexel Brand Guidelines: A 1982 Cambridge FDA Consultancy, Paracelsus & Private Equity

A regulatory consultancy named after Paracelsus.

Parexel began in Cambridge, Massachusetts, in 1982. English Wikipedia names its founders as Josef von Rickenbach, a businessman who had worked as a researcher at Schering-Plough in Lucerne, Switzerland, and the organic chemist Anne B. Sayigh. The name, Wikipedia says, comes from Paracelsus, the sixteenth-century Swiss scientist it credits with starting the field of chemistry.

The first business was advice rather than trials. Parexel set out to help pharmaceutical companies in Japan and Germany take their candidate drugs through the approval process of the US Food and Drug Administration. It also published a newsletter of FDA regulatory news, the U.S. Regulatory Reporter, which Wikipedia says became the foundation of its medical marketing division.

The market around it changed quickly. In 1984, Wikipedia notes, new legislation made it easier to produce generic drugs, and the market for contract research grew fast. In 1986 Parexel began offering contract clinical research services of its own. Von Rickenbach is credited with shaping the firm’s culture and practices, and he led it until 2018.

From consultancy to clinical research organisation.

Through the 1990s Parexel became an international company. Wikipedia says it expanded abroad and set up new practice areas from 1990, opening offices in California, North Carolina, Japan, Italy and Australia during the decade. It listed on Nasdaq in 1995 and used the funding for a run of acquisitions, including six consulting companies, two medical marketing businesses and three European businesses in 1998. By 1999 it had about 4,500 staff in 45 offices.

North Carolina became a second base. A press release from the North Carolina Department of Commerce dated 30 May 2019 traced Parexel’s operations in the state back to 1993 and said it already had more than 600 employees there. The same release announced a second US headquarters in Durham County, with 264 new jobs, housing a range of operational and professional support functions. Parexel’s chief executive at the time, Jamie Macdonald, said in the release that the talent the company had been able to attract to its Durham operation made the area the ideal location to help fuel its future growth. At that point it described Parexel International Corporation Limited as a wholly owned subsidiary of the UK-based West Street Holdings III Limited, with about 20,000 employees worldwide.

The work itself is clinical research on behalf of pharmaceutical and biotechnology companies. Wikipedia describes support across Phase I to IV clinical trials in areas including neuroscience, general medicine, oncology and infectious diseases, with services ranging from the management of trial subjects and investigators to regulatory approval, market access strategy, medical communications and drug safety assessment. The 2019 state release summed the range up as running from clinical trials to regulatory and consulting services to commercial and market access work. By 2018, Wikipedia says, Parexel had completed more than 40 mergers and acquisitions and employed some 18,900 people with operations in 100 countries; it gives a workforce of about 21,000 for 2025. Citing the company’s own 2025 profile, Wikipedia lists its services as clinical trial management, data management, medical writing, biostatistics, pharmacovigilance and regulatory consulting, delivered from more than 84 facilities in 49 countries.

Design and documentation.

Contract research organisations sell a service rather than a product. Drug, biotechnology and medical-device companies hire them to plan and run clinical trials, to test compounds before they reach people, to manage laboratories and to collect and analyse the data that regulators review. Because what they sell is largely invisible, their public image is built from people, places and numbers.

The pictures tend to repeat. Corporate sites and annual reports in the category often show clinicians and patients of different ages and backgrounds talking in calm, well-lit consulting rooms; scientists in lab coats working with pipettes and sample plates; and world maps dotted with the countries and sites where studies run. Data dashboards, charts and screens are common too, reflecting how much of the work is now about managing information as well as patients.

Colour follows the same caution. Blues and greens, from deep navy to soft teal, are frequent choices in health care and research branding, usually set against plenty of white, with a clean sans for names and headings. The aim is to look steady and trustworthy rather than playful, and names are often short, sometimes initials or a single coined word, partly because many of these companies are the product of mergers.

The industry also meets in person. Large gatherings such as the DIA Global Annual Meeting and the SCOPE Summit for clinical-operations staff bring sponsors, research organisations and technology suppliers together, and exhibition stands, panels and presentation slides there are another place where these identities are on show. This guide sets out what can be checked about each company’s history and ownership, and treats every colour and typeface here as our own interpretation.

Two private-equity owners in four years.

Parexel has been privately owned since 2017. In September 2017 the private equity firm Pamplona Capital Management bought the company and took it off the public market, Wikipedia says. Four years later it changed hands again: on 2 July 2021 Parexel announced an agreement to be acquired by the EQT IX fund and Goldman Sachs Asset Management, and the purchase was completed on 15 November 2021.

Under those owners the company has added technology partners and businesses. Wikipedia reports a collaboration with the software company Palantir Technologies in 2024, aimed at data management in clinical trials, and the acquisition in 2026 of Vitrana, a provider of a pharmacovigilance platform, to extend its patient-safety technology. pharmaphorum reported the Vitrana purchase on 30 April 2026, describing Vitrana’s software as a system-agnostic platform that can work with any safety database. Vitrana said it had more than 18,000 active platform users in over 90 countries, and the business was to sit within Parexel’s Patient Safety Services organisation; Parexel said the combination meant customers could use a single partner for both pharmacovigilance technology and services. The same report summed up the ownership history: privately held since Pamplona’s purchase in 2017, then bought by EQT Private Equity and Goldman Sachs Asset Management in 2021. Its Durham site, announced as a second US headquarters in 2019, keeps the company tied to North Carolina, a state whose commerce secretary claimed in that year’s release that it had invented the contract research organisation model.

For a design guide, Parexel shows how a regulatory consultancy with a name borrowed from Paracelsus can carry that name through four decades, a stock-market listing and two private-equity owners. Compare Syneos Health, another North Carolina research organisation taken private, and IQVIA. For this guide we use navy, a mid blue and a pale blue-grey with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Parexel’s identity on hand — save it to a board in the Made Good inspiration library.